期刊文献+

临床药师对1例使用奥曲肽造成低血糖的病例的分析和干预 被引量:6

Participation of Pharmacist in the Analysis and Handle of Hypoglycemia Induced by Octreotid
原文传递
导出
摘要 目的对1例因使用奥曲肽造成低血糖的不良反应的分析和干预过程进行分享,为临床药师工作模式提供参考。方法临床药师发现一例使用奥曲肽引起低血糖的不良反应后,利用专业知识协助医师判断并在查阅相关资料和文献后进行建议和干预,接着对临床医生进行奥曲肽造成低血糖不良反应知晓情况的调查,然后就奥曲肽不良反应及奥曲肽和生长抑素区别进行临床宣教。结果临床医生采纳了临床药师建议,患者低血糖的情况得以纠正,取得较好的临床治疗效果,临床药师的工作模式得到临床的认可。结论临床药师在工作中除了需要具备扎实的专业知识外,还需要掌握沟通的方式和方法,除了协助医生进行药物不良反应的监护外,还需要对工作模式不断探索。 OBJECTIVE To share the process of analysis and intervene the adverse drug reaction (ADR) caused by octreotide, and to provide reference for the work mode of clinical pharmacist. METHODS One case of hypoglycemia possibly caused by octreoti- de was discovered. The clinical pharmacist recommend the doctor to replace octreotide as somatostatin after a review of the relevant in- formation and literatures. Then the clinical pharmacist investigated awareness of hypoglycemia ADR of octreotide among the ICU doc- tom, and introduced the ADR of octreotide and the difference between octreotide and somatostatin among them. RESULTS After the intervention, the hypoglycemia was corrected and the patient was cured and clinical pharmacists' working mode was identified. CON- CLUSION Clinically, pharmacists should not only have good professional knowledge, but also master the ways and means of commu- nication, in addition to assisting doctors monitoring of adverse drug reactions, also need to continue to explore the work mode.
出处 《中国药学杂志》 CAS CSCD 北大核心 2017年第12期1093-1096,共4页 Chinese Pharmaceutical Journal
关键词 奥曲肽 不良反应 临床药师 干预 工作模式 octreotide adverse drug reaction (adr) pharmacist intervention work mode
  • 相关文献

参考文献2

二级参考文献29

  • 1杜文民,王永铭,程能能.药物不良反应的判定与其研究方法(续一)[J].中国药物警戒,2004,1(2):17-20. 被引量:16
  • 2黄宇虹,张伯礼.单一事件药物不良反应的因果关系评价[J].中国临床药理学与治疗学,2007,12(6):697-699. 被引量:4
  • 3Strowski MZ,Parmar RM,Blake AD,et al. Somatostatin inhibits insulin and glucagons secretion via two receptors subtypes:an in vitro study of pancreatic islets from somatostatin receptor 2 knockout mice. Endocrinology,2000,141:111-117.
  • 4Gong AY,Tietz PS,Muff MA,et al. Somatostatin stimulates ductal bile absorption and inhibits ductal bile secretion in mice via SSTR2 on cholangiocytes. Am J Cell Physiol,2003,284:1205-1214.
  • 5Ripamonti C,Panzeri C,Groff L,et al. The role of somatostatin and octreotide in bowel obstruction: pre-clinical and clinical results. Tumori,2001,87:1-9.
  • 6Mulvihill SJ,Pappas TN,Fonkalsrud EW,et al. The effect of somatostatin on experimental intestinal obstruction. Ann Surg,1988,207:169-173.
  • 7Bastounis E,Hadjinikolaou L,Ioannou N,et al. Somatostatin as adjuvant therapy in the management of obstructive ileus. Hepatogastroenterology,1989,36:538-539.
  • 8田少雷,邵庆翔.药物临床试验与GCP实用指南[M].2版.北京:北京大学医学出版社,2010:31.
  • 9SACKETT DL. Clinical Epidemilogy [ M ]. 2nd. Boston: Little, Brown and Company, 1991:297 - 299.
  • 10The Uppsala Monitoring Centre(the UMC). Safety monitoring of medicinal products:guidelines for setting up and running a phar- macovigilance center[ EB/OL]. [ 2013 - 11 - 15 ]. http ://apps. who. int/medicinedocs/en/d/Jh2934e/15, html.

共引文献232

同被引文献89

引证文献6

二级引证文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部